Open AccessReduction in Erythropoietin Resistance After Conversion From Sirolimus to Enteric Coated Mycophenolate Sodium
Author(s) -
Joshua J. Augustine,
Victoria Rodríguez,
Aparna Padiyar,
Kenneth A. Bodziak,
James A. Schulak,
Donald E. Hricik
Publication year - 2008
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0b013e3181814a96
Subject(s) - erythropoietin , medicine , anemia , transferrin saturation , sirolimus , renal function , transplantation , hemoglobin , urology , gastroenterology , iron deficiency
Anemia is a known adverse effect of sirolimus (SRL) therapy. Sirolimus may contribute to anemia by a direct antiproliferative effect or by increasing inflammation, worsening kidney function, or decreasing iron utilization. After observing the need for high dose exogenous erythropoietin dosage in some patients on SRL, we hypothesized that SRL therapy may influence anemia by inducing a state of erythropoietin resistance.